Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1.

@article{Sadowski2015ResultsO,
  title={Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1.},
  author={Samira M. Sadowski and Corina M. Millo and Candice Cottle-Delisle and Roxanne Merkel and Lily A Yang and Peter Herscovitch and Karel Pacak and William F Simonds and Stephen J. Marx and Electron Kebebew},
  journal={Journal of the American College of Surgeons},
  year={2015},
  volume={221 2},
  pages={
          509-17
        }
}
BACKGROUND Screening for neuroendocrine tumors (NETs) in patients with multiple endocrine neoplasia type 1 (MEN1) is recommended to detect primary and metastatic tumors, which can result in significant morbidity and mortality. The utility of somatostatin receptor imaging (68)Gallium-DOTATATE PET/CT in patients with MEN1 is not known. The aim of this study was to prospectively determine the accuracy of (68)Gallium-DOTATATE PET/CT vs (111)In- pentetreotide single-photon emission CT (SPECT)/CT and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor

VIEW 2 EXCERPTS
CITES BACKGROUND & METHODS

Recent Topics Around Multiple Endocrine Neoplasia Type 1

  • Stephen J. Marx
  • Medicine
  • The Journal of clinical endocrinology and metabolism
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND